Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Amortization of Deferred Charges (2016 - 2024)

Neuroone Medical Technologies (NMTC) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $192647.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Amortization of Deferred Charges changed N/A year-over-year to $192647.0, compared with a TTM value of $192647.0 through Sep 2025, changed N/A, and an annual FY2025 reading of $192647.0, up 90.12% over the prior year.
  • Amortization of Deferred Charges was $192647.0 for Q4 2024 at Neuroone Medical Technologies, down from $284637.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $192647.0 in Q4 2024 and bottomed at $192647.0 in Q4 2024.